石洪成教授深耕核医学领域数十年，是集临床、科研、教学与产业创新于一体的领军者。临床一线坚守中，率先构建并践行 “4-3-4” 核医学质量管理体系，斩获上海市政府质量奖，创新提出 “核医学影像循证解析” 理论体系，为精准诊疗奠定坚实基础；学术成果丰硕，出版中、英文专著 4 部，主译 1 部，参编专著 34 部，牵头或参与编写 16 部卫生行业标准、临床指南与专家共识（主笔 12 部），申请 / 授权专利 20 余项，在国内外重要期刊发表论著近 400 篇，其中 SCI 一区顶级期刊 260 余篇及国际行业专家共识 1 篇，主持国家自然科学基金、科技部国家重点研发计划等科研项目 10 余项。作为学科引领者，深耕人才培养与行业赋能，培养硕博士研究生 40 余人、进修生 400 余人，连续举办 9 届（11 次）公益培训，覆盖全国 20 余省市自治区 ，深入基层医院指导工作，助力学科发展。在医工结合与产业创新领域，他依托 “中山 - 联影” 合作平台，建立国内首套大型分子影像设备（PET/CT、PET/MR）验证方案，牵头全球首台国产全身 PET/CT 临床应用国际标准制定，推动国产设备实现 “中国制造、中国验证、国际认可” 的技术飞跃；在国产 PET/CT 与 PET/MR 联合研发中，转化 10 项发明专利，破解多项 “卡脖子” 难题，使国产设备具备国际竞争力，打破国外品牌长期垄断局面。依托全球首台超长轴向视野全身 PET/CT 开展系列探索性研究，发表 40 余篇高质量文章，牵头建立国际公认的 “长轴向视野 PET 肿瘤应用标准”（发表于《European Radiology》），成为该领域国际排头兵；同时牵头制定多部国内 PET/MR 全身显像专家共识，填补国内空白。 20 余次受邀在美国、欧洲核医学年会作特邀报告，赴美国顶尖学府讲学，推介国产设备优势，与 “一带一路” 国家建立学术互访机制，斩获美国核医学研究院荣誉 Fellow、美国 SNMMI 主席杰出贡献奖等国际殊荣，将中国核医学技术与 “智造” 实力推向世界，赢得广泛国际声誉。 科技奖项： 1、《SPECT/CT 技术操作规范的建立与临床应用及推广》获得2021年度“上海医学科技奖”三等奖（第一完成人）。 2、《肝门胆管癌术前评估体系的构建及推广应用》获得2022 年度“上海市医学科技奖”二等奖（第二完成人）。 3、《多模态分子影像设备的自主研发与产业化》获得2024年度“上海市科技进步奖”一等奖（第二完成人）。 发明创造： 1 一种医学图像亮度均一化校正方法 201910683490.2 发明专利 2 基于深度学习的多模态成像扫描协议推荐方法及系统 201910590796.3 发明专利 3 多模医学影像悬浮窗的设置方法、终端及存储介质 202011103950.9 发明专利 4 基于深度学习体征结构的全模态医学影像序列分组方法 202011105228.9 发明专利 5 基于深度学习的影像分析多时相异常特征区域参数的方法 202110209392.2 发明专利 6 基于多核素PET影像不同特征对比减影及量化分析方法 202110209325.0 发明专利 7 基于人工智能的影像质量关键要素评价的智能判别方法 202110215428.8 发明专利 8 全身动态PET显像人体器官生命信息智能一体化分析方法 202210607456.9 发明专利 9 全身动态PET显像人体循环生命信息智能一体化分析方法 202210323516.4 发明专利 10 基于人工智能的 PET 全身定位图像生成及重建方法及系统 202311048377X 发明专利 11 一种体征监测一体化线圈 201820461447.2 实用新型 12 一种具备物理定位功能的PET-CT头托 202120404195.1 实用新型 13 一种具有通气降温功能的改良磁共振线圈 202122258940.9 实用新型 14 医学检查人体工学体位自适应稳定装置 2022214963921 实用新型 15 一种医学检查多功能定位托架 2022214963936 实用新型 16 一种用于全身显像医学影像设备的激光定位装置 202222219528.0 实用新型 17 心脏专用机座椅体位固定装置 202223360205.X 实用新型 18 一种医用可拆卸托臂架 202220329095.1 实用新型 19 一种放射性棒源装置 2022227020386 实用新型 20 一种全视野动态 PET/CT 模块化移动注射车 2023222404859 实用新型 21 核医学装备校正源集成运载装置 202421847027X 实用新型 22 一种多功能核医学装备质控棒源 202421576806.0 实用新型 23 基于人工智能的 PET 全身定位图像生成及重建软件 2023R11L2295190 软件著作 24 一种医学装备质控辅助机器人 202422916423X 发明专利 25 一种医学装备多功能智能机械臂 2024229165073 发明专利 26 核医学装备校正源集成运载装置 202421847027X 发明专利 27 一种多功能核医学装备质控棒源 2024215768060 发明专利 28 基于多核素PET影像不同特征对比减影及量化分析方法 ZL 202110209325.0 发明专利 29 一种全视野动态PET/CT模块化移动注射车 ZL 2023 2 2240485.9 实用新型 30 基于深度学习的影像分析多时相异常特征区域参数的方法 ZL202110209392.2 发明专利 31 基于深度学习体征结构的全模态医学影像序列分组方法 ZL20201105228.9 发明专利 著作： 序号 书名 类型 出版时间 出版社 作者类别 1 《Total-Body PET/CT Prospective Clinical Applications》 著作 2024-12 Springer 主编 2 《全身PET/CT临床应用探索》 著作 2023-12 上海科学技术出版社 主编 3 《PET/CT影像循证解析与操作规范》 著作 2019-01 上海科学技术出版社 主编 4 住院医规培教材《核医学》 教材 2021-04 人民卫生出版社 副主编 重要论文： 1 The added value of dual-time-point 18F-FDG PET/CT imaging in the diagnosis of colorectal cancer liver metastases. 通讯作者 Abdom Radiol (NY). 2020 Apr 45(4):1075-1081. 2 Total-Body PET/CT: Current Applications and Future Perspectives. 通讯作者 AJR Am J Roentgenol. 2020 Aug 215(2):325-337. 3 A Pretargeted Imaging Strategy for Immune Checkpoint Ligand PD-L1 Expression in Tumor Based on Bioorthogonal Diels-Alder Click Chemistry. 通讯作者 Mol Imaging Biol. 2020 Aug 22(4):842-853 4 Diagnostic performance of whole-body bone scintigraphy in combination with SPECT/CT for detection of bone metastases. 通讯作者 Ann Nucl Med. 2020 Aug 34(8):549-558. 5 Synthesis and evaluation of 18F labeled crizotinib derivative [18F]FPC as a novel PET probe for imaging c-MET-positive NSCLC tumor. 通讯作者 Bioorg Med Chem. 2020 Aug 28(15):115577 6 The value of 18 F-FDG PET/CT in diagnosing and localising deep sternal wound infection to guide surgical debridement. 通讯作者 Int Wound J. 2020 Aug 17(4):1019-1027. 7 Performance characteristics of the digital uMI550 PET/CT system according to the NEMA NU2-2018 standard. 通讯作者 EJNMMI Phys. 2020 Jun 26 7(1):43. 8 Imaging characteristics and prognostic values of hepatic epithelioid hemangioendothelioma on 18F-FDG PET/CT. 通讯作者 Clin Exp Med. 2020 Nov 20(4):557-567. 9 The image quality, lesion detectability, and acquisition time of 18F-FDG total-body PET/CT in oncological patients. 通讯作者 Eur J Nucl Med Mol Imaging. 2020 Oct 47(11):2507-2515. 10 Comparison of post-therapeutic sequential 131I whole-body scans in the detection of metastatic thyroid cancer. 通讯作者 Q J Nucl Med Mol Imaging. 2020 Sep 64(3):313-320. 11 Tuberous sclerosis complex (TSC) with epilepsy on 18F-FDG simultaneous PET/MR. 通讯作者 Eur J Nucl Med Mol Imaging. 2020 Sep 47(10):2471-2472. 12 Collision of Solid Pseudopapillary Tumor and Neuroendocrine Tumor of the Pancreas on 18F-FDG PET/CT. 通讯作者 Clin Nucl Med. 2021 Apr 1 46(4):e214-e215 13 Can the BMI-based dose regimen be used to reduce injection activity and to obtain a constant image quality in oncological patients by 18F-FDG total-body PET/CT imaging? 通讯作者 Eur J Nucl Med Mol Imaging. 2021 Dec 49(1):269-278. 14 Bone marrow tracer uptake pattern of PET-CT in multiple myeloma: image interpretation and prognostic value 通讯作者 Ann Hematol. 2021 Dec;100(12) 2979-2988 15 Dynamic monitoring of active calcification in atherosclerosis by 18F-NaF PET imaging. 通讯作者 Int J Cardiovasc Imaging. 2021 Feb 37(2):731-739. 16 A Pretargeted Imaging Strategy for EGFR-Positive Colorectal Carcinoma via Modulation of Tz-Radioligand Pharmacokinetics. 通讯作者 Mol Imaging Biol. 2021 Feb 23(1):38-51. 17 99mTc-labeled Duramycin for detecting and monitoring cardiomyocyte death and assessing atorvastatin cardioprotection in acute myocardial infarction. 通讯作者 Chem Biol Drug Des. 2021 Feb 97(2):210-220. 18 Intra-tumor metabolic heterogeneity of gastric cancer on 18F-FDG PETCT indicates patient survival outcomes. 通讯作者 Clin Exp Med. 2021 Feb 21(1):129-138. 19 Dynamic monitoring of active calcification in atherosclerosis by 18F-NaF PET imaging. 通讯作者 Int J Cardiovasc Imaging. 2021 Feb 37(2):731-739. 20 Intra-tumor metabolic heterogeneity of gastric cancer on 18F-FDG PET/CT indicates patient survival outcomes. 通讯作者 Clin Exp Med. 2021 Feb 21(1):129-138. 21 A Pretargeted Imaging Strategy for EGFR-Positive Colorectal Carcinoma via Modulation of Tz-Radioligand Pharmacokinetics. 通讯作者 Mol Imaging Biol. 2021 Feb 23(1):38-51. 22 99mTc-labeled Duramycin for detecting and monitoring cardiomyocyte death and assessing atorvastatin cardioprotection in acute myocardial infarction. 通讯作者 Chem Biol Drug Des. 2021 Feb 97(2):210-220. 23 a Novel Recombinant Human Thyroid Stimulating Hormone Injection, in Patients With Differentiated Thyroid Carcinoma. 通讯作者 Front Endocrinol (Lausanne). 2021 Feb 17 11:615883. 24 Total-Body PET/Computed Tomography Highlights in Clinical Practice: Experiences from Zhongshan Hospital, Fudan University. 通讯作者 PET Clin. 2021 Jan 16(1):9-14. 25 The value of skeletal standardized uptake values obtained by quantitative single-photon emission computed tomography-computed tomography in differential diagnosis of bone metastases. 通讯作者 Nucl Med Commun. 2021 Jan 42(1):63-67. 26 Ultra-low-activity total-body dynamic PET imaging allows equal performance to full-activity PET imaging for investigating kinetic metrics of 18F-FDG in healthy volunteers. 通讯作者 Eur J Nucl Med Mol Imaging. 2021 Jul 48(8):2373-2383. 27 Total-body 18F-FDG PET/CT scan in oncology patients: how fast could it be? 通讯作者 Eur J Nucl Med Mol Imaging. 2021 Jul 48(8):2384-2394. 28 Internal dosimetry in F-18 FDG PET examinations based on long-time-measured organ activities using total-body PET/CT: does it make any difference from a short-time measurement? 通讯作者 EJNMMI Phys. 2021 Jul 15;8(1) 51 29 Total-body PET/CT using half-dose FDG and compared with conventional PET/CT using full-dose FDG in lung cancer. 通讯作者 Eur J Nucl Med Mol Imaging. 2021 Jun 48(6):1966-1975. 30 NEMA NU2-2012 performance measurements of the United Imaging uPMR790: an integrated PET/MR system. 通讯作者 Eur J Nucl Med Mol Imaging. 2021 Jun 48(6):1726-1735. 31 Investigating the value of pre-treatment 18F-FDG PET/CT in predicting the pathological characteristic of hepatocellular carcinoma and recurrence after liver transplantation. 通讯作者 Abdom Radiol (NY). 2021 Jun 46(6):2490-2497. 32 Role of dual-time point 18F-FDG PET/CT imaging in the primary diagnosis and staging of hilar cholangiocarcinoma 通讯作者 Abdom Radiol (NY). 2021 Sep;46(9) 4138-4147 33 A novel model to assess disease activity in Takayasu arteritis based on 18F-FDG-PET/CT: a Chinese cohort study 通讯作者 Rheumatology (Oxford). 2022 Apr 18;61(SI) SI14-SI22 34 Functional significance of intermediate coronary stenosis in patients with single-vessel coronary artery disease: A comparison of dynamic SPECT coronary flow reserve with intracoronary pressure-derived fractional flow reserve (FFR) 通讯作者 J Nucl Cardiol. 2022 Apr;29(2) 622-629 35 Half-dose versus full-dose 18F-FDG total-body PET/CT in patients with colorectal cancer. 通讯作者 Nucl Med Commun. 2022 Aug 1;43(8) 928-936 36 Diagnostic performance of total-body 18F-FDG PET/CT with fast 2-min acquisition for liver tumours: comparison with conventional PET/CT. 通讯作者 Eur J Nucl Med Mol Imaging. 2022 Aug;49(10) 3538-3546 37 Respiratory-gated PET imaging with reduced acquisition time for suspect malignancies: the first experience in application of total-body PET/CT. 通讯作者 Eur Radiol. 2022 Dec 24 38 A personal acquisition time regimen of 68Ga-DOTATATE total-body PET/CT in patients with neuroendocrine tumor (NET): a feasibility study. 通讯作者 Cancer Imaging. 2022 Dec 29;22(1) 78 39 Longitudinal Positron Emission Tomography Imaging with P2X7 Receptor-Specific Radioligand 18F-FTTM in a Kainic Acid Rat Model of Temporal Lobe Epilepsy. 通讯作者 ACS Chem Neurosci. 2022 Dec 7;13(23) 3512-3522 40 Investigating ultra-low-dose total-body [18F]-FDG PET/CT in colorectal cancer: initial experience. 通讯作者 Eur J Nucl Med Mol Imaging. 2022 Feb 49(3):1002-1011. 41 Reduction of radiation accumulation in salivary glands through oral vitamin C during 68Ga-PSMA-11 total-body dynamic PET/CT imaging. 通讯作者 Nucl Med Commun. 2022 Feb 1 43(2):166-171. 42 Synthesis and biological evaluation of novel PET tracers [18F]AG120 & [18F]AG135 for imaging mutant isocitrate dehydrogenase 1 expression. 通讯作者 Bioorg Med Chem. 2022 Jan 1 53:116525. 43 Targeting Infiltrating Myeloid Cells in Gastric Cancer Using a Pretargeted Imaging Strategy Based on Bio-Orthogonal Diels-Alder Click Chemistry and Comparison with 89Zr-Labeled Anti-CD11b Positron Emission Tomography Imaging. 通讯作者 Mol Pharm. 2022 Jan 3 19(1):246-257. 44 Correlation among maximum standardized 18F-FDG uptake and pathological differentiation, tumor size, and Ki67 in patients with moderately and poorly differentiated intrahepatic cholangiocarcinoma. 通讯作者 Hell J Nucl Med. 2022 Jan-Apr 25(1):38-42 45 P2X7 receptor-specific radioligand 18F-FTTM for atherosclerotic plaque PET imaging 通讯作者 Eur J Nucl Med Mol Imaging. 2022 Jul 49(8):2595-2604 46 Optimizing acquisition times for total-body positron emission tomography/computed tomography with half-dose 18F-fluorodeoxyglucose in oncology patients. 通讯作者 EJNMMI Phys. 2022 Jul 8 9(1):45. 47 Ultrafast 30-s total-body PET/CT scan: a preliminary study. 通讯作者 Eur J Nucl Med Mol Imaging. 2022 Jul;49(8) 2504-2513 48 Short-time total-body dynamic PET imaging performance in quantifying the kinetic metrics of 18F-FDG in healthy volunteers. 通讯作者 Eur J Nucl Med Mol Imaging. 2022 Jul;49(8) 2493-2503 49 Role of 18F-FDG PET/CT imaging in cardiac and pericardial masses. 通讯作者 J Nucl Cardiol. 2022 Jun 29(3):1293-1303. 50 Fluorine-18: Radiochemistry and Target-Specific PET Molecular Probes Design. 通讯作者 Front Chem. 2022 Jun 29 10:884517. 51 Feasibility of Acquisitions Using Total-Body PET/CT with an Ultra-Low 18F-FDG Activity. 通讯作者 J Nucl Med 2022 Jun, 63(6): 959-965. 52 Exploration of the total-body PET/CT reconstruction protocol with ultra-low 18F-FDG activity over a wide range of patient body mass indices. 通讯作者 EJNMMI Phys. 2022 Mar 3 9(1):17. 53 Synthesis and Evaluation of 68Ga-NOTA-COG1410 Targeting to TREM2 of TAMs as a Specific PET Probe for Digestive Tumor Diagnosis. 通讯作者 Anal Chem. 2022 Mar 8 94(9):3819-3830. 54 A novel predictive model for distinguishing mediastinal lymphomas from thymic epithelial tumours. 通讯作者 Eur J Cardiothorac Surg. 2022 Nov 3;62(6) ezac459 55 The feasibility of ultralow-activity 18F-FDG dynamic PET imaging in lung adenocarcinoma patients through total-body PET/CT scanner. 通讯作者 Ann Nucl Med. 2022 Oct;36(10) 887-896 56 124I-Labeled Immuno-PET Targeting hTREM2 for the Diagnosis of Gastric Carcinoma. 通讯作者 Mol Pharm. 2023 Apr 3;20(4) 2235-2244 57 Neuroendocrine Neoplasms: Total-body PET/Computed Tomography. 通讯作者 PET Clin. 2023 Apr;18(2) 251-257 58 An artificial intelligence-driven image quality assessment system for whole-body [18F]FDG PET/CT. 通讯作者 Eur J Nucl Med Mol Imaging. 2023 Apr;50(5) 1318-1328 59 Comparison of 18F-FDG PET/MR and PET/CT for pretreatment TNM staging of hilar cholangiocarcinoma. 通讯作者 Abdom Radiol (NY). 2023 Aug;48(8) 2537-2546 60 One-tenth-activity total-body positron emission tomography versus full-activity imaging in patients with a complex of hepatic malignant tumors: a retrospective study 通讯作者 Quant Imaging Med Surg. 2023 Dec 1;13(12) 8517-8530 61 Dynamic Total-Body PET/CT Imaging Reveals Kinetic Distribution of 68Ga-DOTATATE in Normal Organs. 通讯作者 Contrast Media Mol Imaging. 2023 Jan 18;2023 4722499 62 Ultra-low-dose CT reconstructed with the artificial intelligence iterative reconstruction algorithm (AIIR) in 18F-FDG total-body PET/CT examination: a preliminary study. 通讯作者 EJNMMI Phys. 2023 Jan 2;10(1) 1 63 Ultralow-dose [18F]FDG PET/CT imaging: demonstration of feasibility in dynamic and static images. 通讯作者 Eur Radiol. 2023 Jan 23 64 Exploration of 68Ga-DOTA-MAL as a Versatile Vehicle for Facile Labeling of a Variety of Thiol-Containing Bioactive Molecules. 通讯作者 ACS Omega. 2023 Jan 27;8(5) 4747-4755 65 Expert consensus on oncological [18F]FDG total-body PET/CT imaging (version 1). 通讯作者 Eur Radiol. 2023 Jan;33(1) 615-626 66 Lung invasive adenocarcinoma extended into the left atrium visualized by 18F-FDG PET/CT imaging. 通讯作者 Eur Radiol. 2023 Jan;33(1) 615-626 67 An initial study on the comparison of diagnostic performance of 18F-FDG PET/MR and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer: Focus on pleural invasion. 通讯作者 Rev Esp Med Nucl Imagen Mol (Engl Ed). 2023 Jan-Feb;42(1) 16-23 68 The added value of 18F-FDG PET/MRI multimodal imaging in hepatocellular carcinoma for identifying cytokeratin 19 status. 通讯作者 Abdom Radiol (NY). 2023 Jul;48(7) 2331-2339 69 An exploration of the feasibility and clinical value of half-dose 5-h total-body 18F-FDG PET/CT scan in patients with Takayasu arteritis. 通讯作者 Eur J Nucl Med Mol Imaging. 2023 Jul;50(8) 2375-2385 70 One-stop [18F]FDG and [68Ga]Ga-DOTA-FAPI-04 total-body PET/CT examination with dual-low activity: a feasibility study. 通讯作者 Eur J Nucl Med Mol Imaging. 2023 Jul;50(8) 2271-2281 71 Head-to-head intra-individual comparison of total-body 18F-FDG PET/CT and digital PET/CT in patients with malignant tumor: how sensitive could it be? 通讯作者 Eur Radiol. 2023 Nov;33(11) 7890-7898 72 Deep radiomics-based fusion model for prediction of bevacizumab treatment response and outcome in patients with colorectal cancer liver metastases: a multicentre cohort study 通讯作者 EClinicalMedicine. 2023 Oct 12;65 102271 73 PET vascular activity score for predicting new angiographic lesions in patients with Takayasu arteritis: a Chinese cohort study 通讯作者 Rheumatology (Oxford). 2023 Oct 3;62(10) 3310-3316 74 Quantitative flow ratio derived pullback pressure gradient and CZT-SPECT measured longitudinal flow gradient for hemodynamically significant coronary artery disease 通讯作者 J Nucl Cardiol. 2023 Oct;30(5) 1992-2002 75 Combined early dynamic 18F-FDG PET/CT and conventional whole-body 18F-FDG PET/CT in hepatocellular carcinoma 通讯作者 Abdom Radiol (NY). 2023 Oct;48(10) 3127-3134 76 Dynamic 68Ga-DOTA0-Tyr3-octreotate positron emission tomography-computed tomography for the evaluation of pancreatic neuroendocrine tumors: a pilot study. 通讯作者 Quant Imaging Med Surg. 2023 Sep ;13(9) 5555-5567 77 Different hydration protocols for the quantification of healthy tissue uptake of half-dose 18F-FDG total-body positron emission tomography-computed tomography: a prospective study. 通讯作者 Quant Imaging Med Surg. 2023 Sep ;13(9) 5701-5712 78 Dynamic total-body PET/CT imaging with reduced acquisition time shows acceptable performance in quantification of [18F]FDG tumor kinetic metrics 通讯作者 Eur J Nucl Med Mol Imaging. 2024 Apr;51(5) 1371-1382 79 Comparison of the Accuracy of a Deep Learning Method for Lesion Detection in PET/CT and PET/MRI Images 通讯作者 Mol Imaging Biol. 2024 Aug 14; 80 SPECT/CT imaging: quantifying 99mTc-MDP concentration in the spine and pelvis 通讯作者 Ann Nucl Med. 2024 Aug 18; 81 Low dose optimization for total-body 2-[18F]FDG PET/CT imaging: a single-center study on feasibility based on body mass index stratification 通讯作者 Eur Radiol. 2024 Aug 30; 82 Evaluation of a Positron Emission Tomography Tracer Targeting Colony-Stimulating Factor 1 Receptor for Detecting Pulmonary Inflammation 通讯作者 Mol Pharm. 2024 Aug 5;21(8) 3979-3991 83 Phantom study and clinical application of total-body 18F-FDG PET/CT imaging: How to use small voxel imaging better? 通讯作者 EJNMMI Phys. 2024 Feb 15;11(1) 17 84 A single-center, multi-factor, retrospective study to improve the diagnostic accuracy of primary prostate cancer using [68Ga]Ga-PSMA-11 total-body PET/CT imaging 通讯作者 Eur J Nucl Med Mol Imaging. 2024 Feb;51(3) 919-927 85 Preclinical Evaluation of 99mTc-MAG3-5-Fab Targeting TREM2 in Lung Cancer Mouse Models: A Comparison with 99mTc-MAG3-5-F(ab')2 通讯作者 Mol Pharm. 2024 Jan 1;21(1) 303-312 86 Total-body dynamic PET/CT imaging reveals kinetic distribution of [13N]NH3 in normal organs 通讯作者 Eur J Nucl Med Mol Imaging. 2024 Jul 8; 87 The earliest optimal timing for total-body 68Ga-fibroblast activation protein inhibitor-04 PET scans: an evidence-based single-centre study 通讯作者 Eur Radiol. 2024 Jul;34(7) 4550-4560 88 Parametric net influx rate imaging of 68Ga-DOTATATE in patients with neuroendocrine tumors: assessment of lesion detectability 通讯作者 Ann Nucl Med. 2024 Jul;38(7) 483-492 89 Multiparametric evaluation of mediastinal lymph node metastases in clinical T0-T1c stage non-small-cell lung cancers 通讯作者 Eur J Cardiothorac Surg. 2024 Mar 1;65(3) ezae059 90 Synthesis, Screening, and Evaluation of Theranostic Molecular CPCR4-Based Probe Targeting CXCR4 通讯作者 Mol Pharm. 2024 May 6;21(5) 2415-2424 91 A head-to-head comparison of 18F-FDG PET/CT and 18F-FDG PET/MR in patients with nasopharyngeal carcinoma under different disease settings 通讯作者 Hell J Nucl Med. 2024 May-Aug;27(2) 93-104 92 Comparative benefits of Ki and SUV images in lesion detection during PET/CT imaging 通讯作者 EJNMMI Res. 2024 Oct 16;14(1) 98 93 Exploration the feasibility and additional value of [18F]FDG/[68Ga]Ga-FAPI-04 dual-low-activity-tracer one-stop total-body PET imaging at 34 min post-injection of [68Ga]Ga-FAPI-04 通讯作者 Eur J Nucl Med Mol Imaging. 2024 Sep 25; 94  Expert consensus on workflow of PET/CT with long axial field-of-view.   通讯作者   Eur J Nucl Med Mol Imaging, 52(3),  doi:10.1007/s00259-024-06968-4 95  Eliminating the second CT scan of dual-tracer total-body PET/CT via deep learning-based image synthesis and registration. 通讯作者   Eur J Nucl Med Mol Imaging, 52(7), 0. doi:10.1007/s00259-025-07113-5 96 18F-FDG PET/CT for predicting neoadjuvant PD-L1 blockade monotherapy treatment response in patients with locally advanced esophageal squamous cell carcinoma: a preliminary study.  通讯作者 Eur J Nucl Med Mol Imaging, 52(4), 0. doi:10.1007/s00259-024-07051-8